

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Tuberous Sclerosis Complex Research Program (TSCRCP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Translational Research Award (CTRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526TSCRPCTRA</p>	<p>Independent investigators at all career levels</p>	<ul style="list-style-type: none"> • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC). • Applications may include correlative studies associated with a completed clinical trial. • Projects supported by this award mechanism may include, but are not limited to: <ul style="list-style-type: none"> ○ Studies moving from preclinical to clinical research or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials. ○ Studies advancing clinical trial readiness through the development of biomarkers, clinical endpoints and validation of pharmacokinetics/pharmacodynamics. ○ Pilot clinical trials. ○ New studies improving clinical care of TSC encompassing analysis of real-world clinical practice data. • Research must address one FY26 TSCRCP CTRA focus area. • Clinical Translational Potential, Impact, and Research Strategy are important review criteria. • Preliminary data are required. • Partnering Principal Investigator Option is available. • Submission of a Letter of Intent is required prior to full application submission. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.60 million (M) for total costs* for a single PI. • The maximum allowable funding for the entire period of performance is \$1.90M total costs* for a Partnering PI Option. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time</p> <p>Application: August 6, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration-Hypothesis Development Award (EHDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526TSCRPEHDA</p>	<p>Independent investigators and postdoctoral fellows (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the TSC research field. • Research must address one FY26 TSCRPEHDA focus area. • Research projects must be innovative, feasible and supported by a strong rationale. • Preliminary data are allowed but not required. • Clinical trials are not allowed. • Submission of a Letter of Intent is required prior to full application submission. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$0.35M for total costs.* • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time</p> <p>Application: August 6, 2026 11:59 p.m. Eastern time</p>
<p>Idea Development Award (IDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526TSCRPIDA</p>	<p>Independent investigators</p>	<ul style="list-style-type: none"> • Promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. • Research must address one FY26 TSCRPEHDA focus area. • Impact and Research Strategy are important review criteria. • Preliminary data are required. • Clinical trials are not allowed. • New-to-the-Field Investigators Option supports the continued development of promising independent investigators that are early in their research fields to TSC research. • Submission of a Letter of Intent is required prior to full application submission. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$0.8M for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time</p> <p>Application: August 6, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.